BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:ZM008 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of ZM008\, from ClinicalTrials.gov estimates
 .
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06451497-2826@assetmemo.bio
DTSTAMP:20261121T005259Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:ZM008: Phase 1 readout est. (NCT06451497)
DESCRIPTION:ZM008\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: This is a
  Phase 1 Trial of ZM008\, an Anti-LLT1 Antibody\, Used as Single Agent Fol
 lowed by Combination Treatment With Toripalimab in Patients With Advanced 
 Solid Tumors\nEstimated primary completion: December 2026. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/zm008#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT06451497
URL:https://assetmemo.bio/drug/zm008#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
